Lykos Therapeutics’ Post

Neurizon Therapeutics announced key updates regarding its IND application for NUZ-001 as it navigates FDA review processes. Read More https://lnkd.in/gNYJjAkh #NeurizonTherapeutics, #FDA, #NUZ001, #ALS, #RegulatoryProcess

The FDA approved 50 new therapeutics last year in 2024. The 10-year rolling average now stands at 46.5 novel approvals per year.

Nothing validates more than client testimonials! See how Poseida Therapeutics, Inc. relies on ActiveDisclosure to use the right rules and templates to comply with new reporting requirements.    Learn more about ActiveDisclosure for Proxy: https://lnkd.in/eKeZu6Aw

PPMD is excited to learn that Capricor Therapeutics, Inc. has completed the submission of its rolling Biologics License Application (BLA) to the U.S. FDA seeking full approval for deramiocel for the treatment of #Duchenne cardiomyopathy. Learn more: https://lnkd.in/euFhd53V

Thank you, Aayushi Pratap, for featuring Perspective in this C&EN article on the rise of lead isotopes in the radiopharmaceutical industry. Many in the field are recognizing that, in addition to its clinical benefits, lead offers a relatively easier manufacturing process compared to its competitors. Discover more about the benefits of lead-212 in alpha-particle therapy here: https://bit.ly/4cfRkxB

Have questions about treatment options for glaucoma? We've got answers. The 2024 Glaucoma Pipeline interactive poster, developed under the direction of Arsham Sheybani, MD, and Sahar Bedrood, MD, PhD, offers a view into the various surgical and pharmaceutical options for treating glaucoma as well as those in development. https://bit.ly/491yh9u

I love to see these bio/pharma therapeutics getting close to the FDA finish line. Of course, they all may not get approved, but it takes huge effort to get to this point. Interesting group with antibiotics, small molecules, CAR-T cell therapy, and bi-specific antibody therapy. Let's salute the power of bio/pharma to improve healthcare!

BCBN Feed: Biogen offers to buy Sage Therapeutics for $469M https://lnkd.in/g4jhuW2k Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long slide in its ... ... [...]

In this latest K-Cast series, “Advancing Healthcare With Prescription Drug Therapeutics,” experts offer insights on the future of prescription digital therapeutics (PDTs) and how the landscape might evolve for PDTs over the next 5 years. Watch the series here: https://bit.ly/4dR4oLW #ManagedCare #HealthTech Mahsa Salsabili

If you’re working in Protein Therapeutics, you do not want to miss this webinar by our technical experts Sahil Shah and Mahdi Roohnikan !!